Literature DB >> 11065197

Pharmacokinetic studies of neuromuscular blocking agents: good clinical research practice (GCRP).

J Viby-Mogensen1, D Ostergaard, F Donati, D Fisher, J Hunter, J P Kampmann, A Kopman, J H Proost, S N Rasmussen, L T Skovgaard, F Varin, P M Wright.   

Abstract

In September 1997, an international consensus conference on standardization of studies of neuromuscular blocking agents was held in Copenhagen, Denmark. Based on the conference, a set of guidelines for good clinical research practice (GCRP) in pharmacokinetic studies of neuromuscular blocking agents is presented. Guidelines include: design of the study; relevant patient groups to investigate; test drug administration, sampling and analysis; pharmacokinetic analysis; pharmacokinetic/pharmacodynamic modeling; population pharmacokinetics; statistics; and presentation of pharmacokinetic data. The guidelines are intended to aid those working in this research area; it is hoped that they will assist researchers, editors of scientific papers, and pharmaceutical companies in improving the quality of pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11065197     DOI: 10.1034/j.1399-6576.2000.441002.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  3 in total

1.  The relationship between the target effective site concentration of rocuronium and the degree of recovery from neuromuscular blockade in elderly patients.

Authors:  Xiaochong Fan; Minyu Ma; Zhisong Li; Shengkai Gong; Wei Zhang; Yuanyuan Wen
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

3.  Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery.

Authors:  Juan Fernández-Candil; Pedro L Gambús; Iñaki F Trocóniz; Ricard Valero; Enrique Carrero; Lorea Bueno; Neus Fábregas
Journal:  Eur J Clin Pharmacol       Date:  2008-06-03       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.